SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.

   Biotech / MedicalTrega Biosciences (TRGA), formerly HPIP


Previous 10 
To: Roger Folsom who wrote (145)1/4/2001 11:57:25 AM
From: bob zagorin
   of 152
 
roger, i made a lot of $$$ with TRGA early in the year but sold my current position cheap in dec. to take the loss because the buyout capped the upside. i haven't really researched LION yet. my guess is TRGA sold out cheap as well because the collapse of the equity markets prevented them from getting cash any other way. if so, that would argue LION took advantage of a good opportunity. fwiw.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: bob zagorin who wrote (146)1/4/2001 12:20:57 PM
From: Roger Folsom
   of 152
 
Bob:

Thanks for your response.

If you do research Lion and come up with some conclusions, I hope you post them somewhere on SI!

Unfortunately, my Trega was in a non-taxable IRA and so there was no point in selling.

Michael Murphy's CTSL hotline thought Lion was a reasonably good company, but said he wouldn't be following it.

Cordially, Roger Folsom

Share RecommendKeepReplyMark as Last Read


To: bob zagorin who wrote (88)1/15/2001 10:57:20 AM
From: scaram(o)uche
   of 152
 
For those with an interest in melanocortin receptors, here is a discussion of the Palatin Technologies interest........

eventsdigital.com

requires registration, so the link may dump you at a facilitator?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: scaram(o)uche who wrote (148)2/1/2001 1:19:58 PM
From: bob zagorin
   of 152
 
well i got to book my loss and i've started buying TRGA again. unless i'm missing something, the stock will be worth $1.35 of LEON which is an interesting co.

"...This
transaction values Trega at approximately $35 million, or an estimated $1.35 per
share on a fully diluted basis, subject to certain pre-closing adjustments. The
final exchange ratio will depend on a number of factors, including LION's
average closing price per ADS for the 10 trading days ending 2 trading days
prior to the meeting of Trega stockholders. The $35 million valuation of Trega
presumes that such price will not be lower than $68 or greater than $92. If
LION's average closing price per ADS over this time period is below this range,
the exchange ratio will be based upon a deemed price of $68 per LION ADS; if
such price is above this range, the exchange ratio will be based upon a deemed
price of $92 per LION ADS..."

LEON has sold off some but now appears to be improving. i think i'll be getting LEON worth $68 which is a nice gain from here. not totally sure on all this so i'm not betting the ranch.

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject2/7/2001 12:03:32 PM
From: bob zagorin
   of 152
 
LION bioscience Reports Revenue Increase of 9.7 Million Euros for the First Nine Months of Fiscal Year 2001

HEIDELBERG, Germany, Feb. 7 /PRNewswire/ -- LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO) today reported strong quarterly revenue growth and continuous decrease of quarterly net losses in the current fiscal year, including:

-- A third quarter revenue increase of 161% to 7.7 million Euros compared

to Q3 of fiscal year (FY) 2000.

-- A nine-month revenue increase of 169% to 15.5 million Euros compared to

the same period of FY 2000.

-- A positive December EBIT, which has led to the best quarter in LION

history.

Net sales for the first nine months of FY 2001, ended December 31, 2000, increased by 9.7 million Euros or 169%, to 15.5 million, compared to 5.8 million in the same period of FY 2000. For the third quarter of FY 2001, net sales increased by 161% to 7.7 million Euros, compared to 2.9 million in the same period during FY 2000.

LION's Life Science Informatics (LSI(TM)) business unit increased its sales to 14.2 million Euros in the first nine months of FY 2001 compared to 2.9 million during the same period of the previous year.

Revenues of the information driven drug discovery (iD3(TM)) business unit decreased to 1.3 million Euros compared to 2.9 million in the same period in FY 2000. The reason for this decrease is that, consistent with its strategy, the company moved from fee-for-service projects to internal drug discovery on nuclear receptors at the beginning of 2000.

LION achieved a positive EBIT of 105.000 Euros during the month of December 2000.

Research and development expenses doubled within the first nine months (143% of net sales) to 22.0 million Euros, compared to 10.4 million (181% of net sales) in the same period of FY 2000. SG&A expenses increased by 68% to 8.0 million Euros in the first nine months of FY 2001 compared to 4.7 million in the first nine months of FY 2000.

Excluding non-cash compensation charges, the operating loss amounts to 13.3 million Euros (86% of net sales) for the first nine months ended December 31, 2000, compared to 9.4 million (164% of net sales) during the same period of the FY 2000. Including the previously reported non-cash compensation expenses of 8.7 million Euros that resulted from the conversion of preferred shares to ordinary bearer shares, and an additional non-cash personnel expense of 1.3 million for outstanding stock options, the company has realized an operating loss of 23.3 million (151% of net sales).

Key Partnerships Strengthen Growth

In October 2000, LION formed a strategic alliance with Celera Inc. Rockville, MD (NYSE: CRA). Celera uses LION's SRS technology as base technology for its Celera Discovery System (CDS) for the worldwide distribution of human genome data.

On October 16, 2000 LION expanded its i-biology(TM)collaboration with Bayer to include the area of pharmacophore informatics. This landmark collaboration is designed to integrate genomics and chemical sciences in a novel and unique way to better predict biological activities from chemical structures.

On December 27, 2000 LION bioscience announced that it had entered into a merger agreement to acquire Trega Biosciences Inc., San Diego, CA (Nasdaq: TRGA) in a stock for stock transaction. LION has agreed to acquire 100% of the equity of Trega in exchange for LION American Depositary Shares (ADS). LION and Trega will combine complementary technologies and products, which are expected to significantly enhance LION's position as a leading provider of comprehensive solutions for enterprise-wide data integration, data analysis and information management solutions for the Life Sciences industry.

LION has successfully expanded its operations during this period in the USA, Europe and Japan through new customer contracts. After the first nine months of the FY 2001, the company achieved its operational goals.

The comprehensive report for the first nine months of the fiscal year can be downloaded from the LION web site: lionbioscience.com (see section "Financial Information"), or can be requested directly from the company.

About LION bioscience

LION bioscience AG (http://www.lionbioscience.com) is a pioneer in the field of enterprise-wide R&D data analysis and information management systems and solutions for the life sciences and, ultimately, the healthcare industry.

To date, LION AG has established numerous alliances in informatics and genomics with leading Life Science research companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, Janssen, Merck Inc., Nestle, Novartis, Paradigm, Pharmacia & Upjohn, Pfizer, Sumitomo Pharmaceuticals and Tripos.

All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on August 9, 2000. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.

LION bioscience(R), i-biology(TM) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.

LION bioscience Noonan/Russo Communications

Klaus Sprockamp Ernie Knewitz

CFO/COO 212-696-4455 x204

49-6221-4038-192 ernie.knewitz@noonanrusso.com

klaus.sprockamp@lionbioscience.com

LION bioscience

Dr. Alexander Asam, MBA

Head of Investor Relations

49-6221-4038-215

alexander.asam@lionbioscience.com

SOURCE LION biosciences AG

CO: LION biosciences AG; Celera Inc.; Trega Biosciences Inc.

ST: Germany

IN: MTC BIO

SU: ERN

02/07/2001 02:00 EST prnewswire.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject2/7/2001 12:03:32 PM
From: bob zagorin
   of 152
 
Want to send this story to another AOL member? Click on the heart at the top of this window.

LION bioscience Reports Revenue Increase of 9.7 Million Euros for the First Nine Months of Fiscal Year 2001


HEIDELBERG, Germany, Feb. 7 /PRNewswire/ -- LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO) today reported strong quarterly revenue growth and continuous decrease of quarterly net losses in the current fiscal year, including:

-- A third quarter revenue increase of 161% to 7.7 million Euros compared

to Q3 of fiscal year (FY) 2000.

-- A nine-month revenue increase of 169% to 15.5 million Euros compared to

the same period of FY 2000.

-- A positive December EBIT, which has led to the best quarter in LION

history.

Net sales for the first nine months of FY 2001, ended December 31, 2000, increased by 9.7 million Euros or 169%, to 15.5 million, compared to 5.8 million in the same period of FY 2000. For the third quarter of FY 2001, net sales increased by 161% to 7.7 million Euros, compared to 2.9 million in the same period during FY 2000.

LION's Life Science Informatics (LSI(TM)) business unit increased its sales to 14.2 million Euros in the first nine months of FY 2001 compared to 2.9 million during the same period of the previous year.

Revenues of the information driven drug discovery (iD3(TM)) business unit decreased to 1.3 million Euros compared to 2.9 million in the same period in FY 2000. The reason for this decrease is that, consistent with its strategy, the company moved from fee-for-service projects to internal drug discovery on nuclear receptors at the beginning of 2000.

LION achieved a positive EBIT of 105.000 Euros during the month of December 2000.

Research and development expenses doubled within the first nine months (143% of net sales) to 22.0 million Euros, compared to 10.4 million (181% of net sales) in the same period of FY 2000. SG&A expenses increased by 68% to 8.0 million Euros in the first nine months of FY 2001 compared to 4.7 million in the first nine months of FY 2000.

Excluding non-cash compensation charges, the operating loss amounts to 13.3 million Euros (86% of net sales) for the first nine months ended December 31, 2000, compared to 9.4 million (164% of net sales) during the same period of the FY 2000. Including the previously reported non-cash compensation expenses of 8.7 million Euros that resulted from the conversion of preferred shares to ordinary bearer shares, and an additional non-cash personnel expense of 1.3 million for outstanding stock options, the company has realized an operating loss of 23.3 million (151% of net sales).

Key Partnerships Strengthen Growth

In October 2000, LION formed a strategic alliance with Celera Inc. Rockville, MD (NYSE: CRA). Celera uses LION's SRS technology as base technology for its Celera Discovery System (CDS) for the worldwide distribution of human genome data.

On October 16, 2000 LION expanded its i-biology(TM)collaboration with Bayer to include the area of pharmacophore informatics. This landmark collaboration is designed to integrate genomics and chemical sciences in a novel and unique way to better predict biological activities from chemical structures.

On December 27, 2000 LION bioscience announced that it had entered into a merger agreement to acquire Trega Biosciences Inc., San Diego, CA (Nasdaq: TRGA) in a stock for stock transaction. LION has agreed to acquire 100% of the equity of Trega in exchange for LION American Depositary Shares (ADS). LION and Trega will combine complementary technologies and products, which are expected to significantly enhance LION's position as a leading provider of comprehensive solutions for enterprise-wide data integration, data analysis and information management solutions for the Life Sciences industry.

LION has successfully expanded its operations during this period in the USA, Europe and Japan through new customer contracts. After the first nine months of the FY 2001, the company achieved its operational goals.

The comprehensive report for the first nine months of the fiscal year can be downloaded from the LION web site: lionbioscience.com (see section "Financial Information"), or can be requested directly from the company.

About LION bioscience

LION bioscience AG (http://www.lionbioscience.com) is a pioneer in the field of enterprise-wide R&D data analysis and information management systems and solutions for the life sciences and, ultimately, the healthcare industry.

To date, LION AG has established numerous alliances in informatics and genomics with leading Life Science research companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, Janssen, Merck Inc., Nestle, Novartis, Paradigm, Pharmacia & Upjohn, Pfizer, Sumitomo Pharmaceuticals and Tripos.

All statements in this press release that are not historical are forward-looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on August 9, 2000. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.

LION bioscience(R), i-biology(TM) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners.

LION bioscience Noonan/Russo Communications

Klaus Sprockamp Ernie Knewitz

CFO/COO 212-696-4455 x204

49-6221-4038-192 ernie.knewitz@noonanrusso.com

klaus.sprockamp@lionbioscience.com

LION bioscience

Dr. Alexander Asam, MBA

Head of Investor Relations

49-6221-4038-215

alexander.asam@lionbioscience.com

SOURCE LION biosciences AG

CO: LION biosciences AG; Celera Inc.; Trega Biosciences Inc.

ST: Germany

IN: MTC BIO

SU: ERN

02/07/2001 02:00 EST prnewswire.com

Share RecommendKeepReplyMark as Last Read


To: E.J. Neitz Jr who started this subject3/12/2001 2:21:03 PM
From: bob zagorin
   of 152
 
Trega Biosciences Announces Stockholder Approval Of Merger With LION bioscience

SAN DIEGO, March 12 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA) today announced that its stockholders have approved its merger with LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO). The acquisition, which was first announced on December 27, 2000, is expected to close this week. Under the terms of the merger agreement between Trega and LION, LION will acquire all of the outstanding stock of Trega in exchange for LION American Depositary Shares (ADSs).

Trega Biosciences, Inc. is a premier provider of products that accelerate and improve drug discovery through its iDiscovery(TM) technologies that link biology and chemistry with information technologies. Trega's iDEA(TM) family of information-based models simulate, in silico, how drug candidates will be processed in the body, thereby enabling selection of those with optimal characteristics for clinical development. Together with its iDEA(TM) products, Trega's ChemFolio(R) libraries of information-enhanced small molecules are designed to facilitate the identification and optimization of drug candidates. For additional information on Trega, please visit our web site at trega.com.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether the proposed merger will be completed or successful, whether regulatory approvals can be obtained for products discovered and developed, if any, the impact of competitive products and pricing, whether any other corporate collaborations or alliances will be agreed to, expanded or successful, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Actual results may differ materially from those projected. Trega disclaims, however, any intent or obligation to update these forward-looking statements.

LION bioscience AG (http://www.lionbioscience.com) is a pioneer in the field of enterprise-wide R&D data analysis (biology - chemistry - preclinical) and integrated information management systems and solutions for the life sciences and, ultimately, the healthcare industry. It employs these solutions also for its own drug discovery research. i-biology(R) is LION's corporate-wide, cross-discipline research IT-management solution which enables research organizations to more effectively manage and use the knowledge that is currently distributed across their organizations. Founded in 1997, the company today has more than 300 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK and Cambridge, MA, USA. To date, LION AG has established numerous partnerships with leading Life Science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.

Share RecommendKeepReplyMark as Last Read
Previous 10